Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608275 | 0.91 | TSHR (0.46) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL12716719 | 0.89 | TSHR (0.40) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL10080352 | 0.85 | TSHR (0.43) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL23225387 | 0.82 | SMN1; SMN2 (0.41) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL2608259 | 0.82 | TSHR (0.50) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL820628 | 0.81 | TSHR (0.50) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL2608269 | 0.81 | MAPT (0.41) | TSHRMAPTALDH1A1LMNAEPHX2 | |
| SCHEMBL9563945 | 0.80 | SMN1; SMN2 (0.47) | TSHRHPGDMAPTALDH1A1TP53 | |
| SCHEMBL2608291 | 0.80 | TSHR (0.40) | TSHRMAPTALDH1A1LMNATHRB | |
| SCHEMBL2608263 | 0.79 | ZDHHC20 (0.39) | TSHRMAPTALDH1A1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345180-B2 | Display medium for assessment and method for manufacturing same | ZEON CORPORATION (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20190184732-A1 | DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME | ZEON CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-8262932-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, polymer and film | FUJIFILM CORPORATION (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | ZEON CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110140041-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS | CCNB1, CCNT1, CCNB2 | TSHR 4683/4885HPGD 4583/4885MAPT 303/4885 |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | TSHR 4760/4885HPGD 4657/4885MAPT 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.